Colombianitos Inc

Atlanta, GA ·EIN 58-2646131 ·Grant funding profile from IRS 990 filings

$20K received 5 funders 5 grants · 2022–2024

Who funds Colombianitos Inc?

Colombianitos Inc is funded by 5 grantmakers, led by America Viva Alliance Corp ($10K), Pledgeling Foundation ($7K), Cape Legacy Foundation Inc ($3K). In total, IRS Form 990 filings record $20K in grants to Colombianitos Inc between 2022–2024.

FunderTotal givenGrantsYears
America Viva Alliance Corp$10,01812023
Pledgeling Foundation$6,94312023
Cape Legacy Foundation Inc$2,60012024
Gennx Foundation Inc$75012024
The Pfizer Foundation Inc$2512022

What grants has Colombianitos Inc received?

Individual grants from IRS Form 990 filings, newest first

YearFunderPurposeAmount
2024Cape Legacy Foundation Incgeneral purpose$2,600
2024Gennx Foundation IncTO FURTHER THAT TAX EXEMPT MISSION OF THE ORGANIZATION$750
2023America Viva Alliance CorpGeneral support$10,018
2023Pledgeling FoundationGENERAL$6,943
2022The Pfizer Foundation IncMATCHING GIFTS$25

Frequently Asked Questions

Who funds Colombianitos Inc?

Colombianitos Inc is funded by 5 grantmakers, led by America Viva Alliance Corp ($10K), Pledgeling Foundation ($7K), Cape Legacy Foundation Inc ($3K). In total, IRS Form 990 filings record $20K in grants to Colombianitos Inc between 2022–2024.

Who is Colombianitos Inc's largest funder?

America Viva Alliance Corp is the largest recorded funder of Colombianitos Inc, with $10K across 1 grant (2023).

How much grant funding has Colombianitos Inc received?

IRS 990 filings record $20K in grants to Colombianitos Inc across 5 grants from 5 funders between 2022–2024. Filings are published on a delay, so recent grants may not appear yet.

Looking for funders like Colombianitos Inc's?

Grantable's AI matches your organization against 200,000+ grantmakers — including every funder on this page — using their real giving history.

Grant data is drawn from IRS Form 990 filings via Grantable's GrantGraph™. Filings are published on a delay; recent grants may not appear yet.